Bipolar Disorders in Saudi Arabia: What Do We Know So Far?

被引：0
|
作者：
Almadani, Ahmad H. [1 ,2 ]
Alhadi, Ahmad N. [1 ,2 ,3 ]
Aldawood, Buthainah D. [4 ]
Aleissa, Mariam M. [5 ,6 ]
Alosaimi, Fahad D. [1 ,2 ]
机构：
[1] King Saud Univ, Coll Med, Dept Psychiat, Riyadh, Saudi Arabia
[2] King Saud Univ, King Saud Univ Med City, Dept Psychiat, Riyadh, Saudi Arabia
[3] King Saud Univ, Coll Med, SABIC Psychol Hlth Res & Applicat Chair, Riyadh, Saudi Arabia
[4] Princess Nourah bint Abdulrahman Univ, Coll Hlth & Rehabil Sci, Dept Clin Psychol, Riyadh, Saudi Arabia
[5] Publ Hlth Lab, Dept Mol Genet, Publ Hlth Author, Riyadh, Saudi Arabia
[6] Alfaisal Univ, Med Sch, Riyadh, Saudi Arabia
来源：
SAUDI JOURNAL OF MEDICINE & MEDICAL SCIENCES | 2025年 / 13卷 / 01期
关键词：
Bipolar disorders; clinical manifestations; epidemiology; etiology; psychotropic medications; Saudi Arabia; OUTPATIENT PSYCHIATRIC SETTINGS; PREVALENCE; PATTERNS; INPATIENT; DIAGNOSES; STIGMA;
D O I：
10.4103/sjmms.sjmms_306_24
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Bipolar disorders (BP) are prevalent neuropsychiatric illnesses affecting 1%-5% of the global population and about 3% of the Saudi population. They are associated with significant comorbidities and negative consequences. Despite being common mental health conditions in Saudi Arabia, stigma persists, with weak character, supernatural beliefs, and weak faith considered as causes. In addition, Saudi patients with BP have been reported to seek help from non-psychiatric healthcare professionals and faith healers. More data are required on BP from Saudi Arabia, including the genetic aspects and their treatment approaches. This narrative review paper explores the epidemiology and clinical manifestations, etiology and biological mechanisms, public knowledge and awareness of the illnesses, and treatment of BP in Saudi Arabia.
引用
收藏
页码：1 / 6
页数：6
相关论文
共 50 条
  • [1] Vitamin D and Temporomandibular Disorders: What Do We Know So Far?
    Kui, Andreea
    Buduru, Smaranda
    Labunet, Anca
    Balhuc, Silvia
    Negucioiu, Marius
    NUTRIENTS, 2021, 13 (04)
  • [2] Refractory hypertension: what do we know so far?
    Muxfeldt, Elizabeth Silaid
    Chedier, Bernardo
    JOURNAL OF HUMAN HYPERTENSION, 2021, 35 (03) : 181 - 183
  • [3] Eosinophilic Esophagitis-What Do We Know So Far?
    Wasik, Jakub
    Malecka-Wojciesko, Ewa
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (06)
  • [4] RISK FACTORS FOR THYROID CANCER: WHAT DO WE KNOW SO FAR?
    Crncic, Tatjana Bogovic
    Tomas, Maja Ilic
    Girotto, Neva
    Ivankovic, Svjetlana Grbac
    ACTA CLINICA CROATICA, 2020, 59 : 66 - 72
  • [5] Toxoplasma gondii in Marine Life of Italian Coasts, What Do We Know So Far?
    Rodriguez-Fernandez, Veronica
    Bruschi, Fabrizio
    PARASITOLOGIA, 2023, 3 (04): : 364 - 373
  • [6] Transgender Health in the Middle East Region: What Do We Know So Far? A Literature Review
    Farah, Stephanie
    Rizk, Youssef
    Azar, Madona
    TRANSGENDER HEALTH, 2024, 9 (05) : 375 - 388
  • [7] Schizophrenia and eating disorders: What do we know?
    Mathieu, Sasha
    Varescon, Isabelle
    ANNALES MEDICO-PSYCHOLOGIQUES, 2018, 176 (03): : 231 - 235
  • [8] A narrative review of functional dysphagia-what we know so far
    Travers, Paul M.
    Zheng, Ting
    Devault, Kenneth R.
    Pang, Maoyin
    ANNALS OF ESOPHAGUS, 2024, 7
  • [9] What do we know about why women bleed and what do we not know?
    James, Andra H.
    James, Paula D.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2024, 22 (02) : 315 - 322
  • [10] Systemic lupus erythematosus and COVID-19: what we know so far
    Ramirez, Giuseppe. A. A.
    Moroni, Luca
    Della-Torre, Emanuel
    Gerosa, Maria
    Beretta, Lorenzo
    Bozzolo, Enrica. P. P.
    Dagna, Lorenzo
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (03)
12345